Lifestyle Interventions to Prevent Type 2 Diabetes: A Systematic Review of Economic Evaluation Studies

Koffi Alouki, Hélène Delisle, Clara Bermúdez-Tamayo, Mira Johri, Koffi Alouki, Hélène Delisle, Clara Bermúdez-Tamayo, Mira Johri

Abstract

Objective. To summarize key findings of economic evaluations of lifestyle interventions for the primary prevention of type 2 diabetes (T2D) in high-risk subjects. Methods. We conducted a systematic review of peer-reviewed original studies published since January 2009 in English, French, and Spanish. Eligible studies were identified through relevant databases including PubMed, Medline, National Health Services Economic Evaluation, CINHAL, EconLit, Web of sciences, EMBASE, and the Latin American and Caribbean Health Sciences Literature. Studies targeting obesity were also included. Data were extracted using a standardized method. The BMJ checklist was used to assess study quality. The heterogeneity of lifestyle interventions precluded a meta-analysis. Results. Overall, 20 studies were retained, including six focusing on obesity control. Seven were conducted within trials and 13 using modeling techniques. T2D prevention by physical activity or diet or both proved cost-effective according to accepted thresholds, except for five inconclusive studies, three on diabetes prevention and two on obesity control. Most studies exhibited limitations in reporting results, primarily with regard to generalizability and justification of selected sensitivity parameters. Conclusion. This confirms that lifestyle interventions for the primary prevention of diabetes are cost-effective. Such interventions should be further promoted as sound investment in the fight against diabetes.

Figures

Figure 1
Figure 1
Flowchart of overall systematic search process.
Figure 2
Figure 2
Limitations of studies as result of quality assessment.

References

    1. Popkin B. M. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. American Journal of Clinical Nutrition. 2006;84(2):289–298.
    1. IDF. International Diabetes Federation Diabetes Atlas. 6th. International Diabetes Federation (IDF); 2014.
    1. Mbanya J. C. N., Motala A. A., Sobngwi E., Assah F. K., Enoru S. T. Diabetes in sub-Saharan Africa. The Lancet. 2010;375(9733):2254–2266. doi: 10.1016/S0140-6736(10)60550-8.
    1. Kirigia J. M., Sambo H. B., Sambo L. G., Barry S. P. Economic burden of diabetes mellitus in the WHO African region. BMC International Health and Human Rights. 2009;9, article 6 doi: 10.1186/1472-698x-9-6.
    1. Ankotche A., Binan Y., Leye A., et al. Graves conséquences du coût financier du diabète sur sa prise en charge, en dehors des complications, en Afrique sub-saharienne : l’exemple de la Côte-d’Ivoire. Médecine des Maladies Métaboliques. 2009;3(1):100–105. doi: 10.1016/S1957-2557(09)70126-9.
    1. Gong Q., Gregg E. W., Wang J., et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54(2):300–307. doi: 10.1007/s00125-010-1948-9.
    1. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A. D., Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) Diabetologia. 2006;49(2):289–297. doi: 10.1007/s00125-005-0097-z.
    1. Orchard T. J., Temprosa M., Barrett-Connor E., et al. Long-term effects of the diabetes prevention program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabetic Medicine. 2013;30(1):46–55. doi: 10.1111/j.1464-5491.2012.03750.x.
    1. Islam S. M., Purnat T. D., Phuong N. T., Mwingira U., Schacht K., Fröschl G. Non-Communicable Diseases (NCDs) in developing countries: a symposium report. Globalization and Health. 2014;10, article 81 doi: 10.1186/s12992-014-0081-9.
    1. Cohen D. J., Reynolds M. R. Interpreting the results of cost-effectiveness studies. Journal of the American College of Cardiology. 2008;52(25):2119–2126. doi: 10.1016/j.jacc.2008.09.018.
    1. WHO. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. 2010.
    1. Li R., Zhang P., Barker L. E., Chowdhury F. M., Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872–1894. doi: 10.2337/dc10-0843.
    1. Saha S., Gerdtham U.-G., Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. International Journal of Environmental Research and Public Health. 2010;7(8):3150–3195. doi: 10.3390/ijerph7083150.
    1. Gaziano T. A., Galea G., Reddy K. S. Scaling up interventions for chronic disease prevention: the evidence. The Lancet. 2007;370(9603):1939–1946. doi: 10.1016/s0140-6736(07)61697-3.
    1. Husereau D., Drummond M., Petrou S., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. The BMJ. 2013;346, article f1049 doi: 10.1136/bmj.f1049.
    1. Herman W. H., Edelstein S. L., Ratner R. E., et al. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–730. doi: 10.2337/dc11-1468.
    1. Herman W. H., Edelstein S. L., Ratner R. E., et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. American Journal of Managed Care. 2013;19(3):194–202.
    1. van Wier M. F., Lakerveld J., Bot S. D. M., Chinapaw M. J. M., Nijpels G., van Tulder M. W. Economic evaluation of a lifestyle intervention in primary care to prevent type 2 diabetes mellitus and cardiovascular diseases: a randomized controlled trial. BMC Family Practice. 2013;14(1, article 45) doi: 10.1186/1471-2296-14-45.
    1. Sagarra R., Costa B., Cabré J. J., Solà-Morales O., Barrio F. Lifestyle interventions for diabetes mellitus type 2 prevention. Revista Clínica Española. 2014;214(2):59–68. doi: 10.1016/j.rceng.2013.11.003.
    1. Kolu P., Raitanen J., Rissanen P., Luoto R. Cost-effectiveness of lifestyle counselling as primary prevention of gestational diabetes mellitus: findings from a cluster-randomised trial. PLoS ONE. 2013;8(2) doi: 10.1371/journal.pone.0056392.e56392
    1. Oostdam N., Bosmans J., Wouters M. G. A. J., Eekhoff E. M. W., van Mechelen W., van Poppel M. N. M. Cost-effectiveness of an exercise program during pregnancy to prevent gestational diabetes: results of an economic evaluation alongside a randomised controlled trial. BMC Pregnancy and Childbirth. 2012;12, article 64 doi: 10.1186/1471-2393-12-64.
    1. Liu X., Li C., Gong H., et al. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health. 2013;13, article 729 doi: 10.1186/1471-2458-13-729.
    1. Png M. E., Yoong J. S., Petta S. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes. PLoS ONE. 2014;9(9) doi: 10.1371/journal.pone.0107225.e107225
    1. Bertram M. Y., Lim S. S., Barendregt J. J., Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53(5):875–881. doi: 10.1007/s00125-010-1661-8.
    1. Mortaz S., Wessman C., Duncan R., Gray R., Badawi A. Impact of screening and early detection of impaired fasting glucose tolerance and type 2 diabetes in Canada: a Markov model simulation. Clinicoecon and Outcomes Research. 2012;4:91–97. doi: 10.2147/ceor.s30547.
    1. Johansson P., Östenson C.-G., Hilding A. M., Andersson C., Rehnberg C., Tillgren P. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. International Journal of Technology Assessment in Health Care. 2009;25(3):350–358. doi: 10.1017/s0266462309990079.
    1. Neumann A., Schwarz P., Lindholm L. Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling. Cost Effectiveness and Resource Allocation. 2011;9(1, article 17) doi: 10.1186/1478-7547-9-17.
    1. Palmer A. J., Tucker D. M. D. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Primary Care Diabetes. 2012;6(2):109–121. doi: 10.1016/j.pcd.2011.10.006.
    1. Smith K. J., Hsu H. E., Roberts M. S., et al. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005–2007. Preventing Chronic Disease. 2010;7(5, article A109)
    1. Tsai A. G., Wadden T. A., Volger S., et al. Cost-effectiveness of a primary care intervention to treat obesity. International Journal of Obesity. 2013;37(supplement 1):S31–S37. doi: 10.1038/ijo.2013.94.
    1. Cobiac L., Vos T., Veerman L. Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program. Australian and New Zealand Journal of Public Health. 2010;34(3):240–247. doi: 10.1111/j.1753-6405.2010.00520.x.
    1. Miners A., Harris J., Felix L., Murray E., Michie S., Edwards P. An economic evaluation of adaptive e-learning devices to promote weight loss via dietary change for people with obesity. BMC Health Services Research. 2012;12, article 190 doi: 10.1186/1472-6963-12-190.
    1. Forster M., Veerman J. L., Barendregt J. J., Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. International Journal of Obesity. 2011;35(8):1071–1078. doi: 10.1038/ijo.2010.246.
    1. Lewis L., Taylor M., Broom J., Johnston K. L. The cost-effectiveness of the Lighter Life weight management programme as an intervention for obesity in England. Clinical Obesity. 2014;4(3):180–188. doi: 10.1111/cob.12060.
    1. Anokye N. K., Trueman P., Green C., Pavey T. G., Hillsdon M., Taylor R. S. The cost-effectiveness of exercise referral schemes. BMC Public Health. 2011;11, article 954 doi: 10.1186/1471-2458-11-954.
    1. Drummond M. F., Jefferson T. O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal. 1996;313(7052):275–283. doi: 10.1136/bmj.313.7052.275.
    1. Knowler W. C., Fowler S. E., Hamman R. F., et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes study. The Lancet. 2009;374(9702):1677–1686. doi: 10.1016/s0140-6736(09)61457-4.
    1. Tuomilehto J., Lindström J., Eriksson J. G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine. 2001;344(18):1343–1350. doi: 10.1056/nejm200105033441801.
    1. Li G., Zhang P., Wang J., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. The Lancet. 2008;371(9626):1783–1789. doi: 10.1016/S0140-6736(08)60766-7.
    1. NICE. Modelling the Cost Effectiveness of Physical Activity Interventions. London, UK: National Institute for Health and Clinical Excellence (NICE); 2006.
    1. Johns B., Adam T., Evans D. B. Enhancing the comparability of costing methods: cross-country variability in the prices of non-traded inputs to health programmes. Cost Effectiveness and Resource Allocation. 2006;4, article 8 doi: 10.1186/1478-7547-4-8.
    1. Walker D., Fox-Rushby J. A. Allowing for uncertainty in economic evaluations: qualitative sensitivity analysis. Health Policy and Planning. 2001;16(4):435–443. doi: 10.1093/heapol/16.4.435.
    1. Brisson M., Edmunds W. J. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Medical Decision Making. 2006;26(5):434–446. doi: 10.1177/0272989x06290485.
    1. Goldney R. D., Phillips P. J., Fisher L. J., Wilson D. H. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27(5):1066–1070. doi: 10.2337/diacare.27.5.1066.
    1. McDonough C. M., Tosteson A. N. A. Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. PharmacoEconomics. 2007;25(2):93–106. doi: 10.2165/00019053-200725020-00003.
    1. Echouffo-Tcheugui J.-B., Kengne A.-P. A United Nation high level meeting on chronic non-communicable diseases: utility for Africa? Pan African Medical Journal. 2012;11, article 71
    1. Drummond M. F., Sculpher M. J., Torrance G. W., O'Brien J. B., Stoddart L. G. Methods for the Economic Evaluation of Health Care Programmes. 3rd. New York, NY, USA: Oxford University Press; 2005.
    1. ACMTS. Lignes Directrices de l'Évaluations Economique des Techonologies de Santé au Canada. 3rd. Ottawa, Canada: Agence Canadienne des Médicaments et des Technologies de la Santé (ACMTS); 2006.
    1. Sutton L., Karan A., Mahal A. Evidence for cost-effectiveness of lifestyle primary preventions for cardiovascular disease in the Asia-Pacific Region: a systematic review. Globalization and Health. 2014;10(1, article 79) doi: 10.1186/s12992-014-0079-3.
    1. Echouffo-Tcheugui J. B., Ali M. K., Griffin S. J., Narayan K. M. V. Screening for type 2 diabetes and dysglycemia. Epidemiologic Reviews. 2011;33(1):63–87. doi: 10.1093/epirev/mxq020.
    1. Eddy D. M. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. PharmacoEconomics. 2006;24(9):837–844. doi: 10.2165/00019053-200624090-00002.
    1. Philips Z., Ginnelly L., Sculpher M., et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment. 2004;8(36):1–158.
    1. Kahn R., Davidson M. B. The reality of type 2 diabetes prevention. Diabetes Care. 2014;37(4):943–949. doi: 10.2337/dc13-1954.
    1. Wareham N. J. Mind the gap: efficacy versus effectiveness of lifestyle interventions to prevent diabetes. The Lancet Diabetes & Endocrinology. 2015;3(3):160–161. doi: 10.1016/s2213-8587(15)70015-x.
    1. Jackson S. L., Long Q., Rhee M. K., et al. Weight loss and incidence of diabetes with the Veterans Health Administration MOVE! lifestyle change programme: an observational study. The Lancet Diabetes & Endocrinology. 2015;3(3):173–180. doi: 10.1016/S2213-8587(14)70267-0.
    1. Whittemore R. A systematic review of the translational research on the Diabetes Prevention Program. Translational Behavioral Medicine. 2011;1(3):480–491. doi: 10.1007/s13142-011-0062-y.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する